- Home
- SACH vs TPST Comparison
SACH vs TPST Comparison
Compare SACH & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- TPST
- Stock Information
- Founded
- SACH 2010
- TPST 2011
- Country
- SACH United States
- TPST United States
- Employees
- SACH N/A
- TPST N/A
- Industry
- SACH Real Estate Investment Trusts
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- SACH Real Estate
- TPST Health Care
- Exchange
- SACH Nasdaq
- TPST Nasdaq
- Market Cap
- SACH 54.4M
- TPST 45.5M
- IPO Year
- SACH 2017
- TPST N/A
- Fundamental
- Price
- SACH $1.07
- TPST $10.14
- Analyst Decision
- SACH Hold
- TPST Hold
- Analyst Count
- SACH 4
- TPST 3
- Target Price
- SACH $2.00
- TPST $30.00
- AVG Volume (30 Days)
- SACH 207.5K
- TPST 51.9K
- Earning Date
- SACH 11-13-2025
- TPST 11-11-2025
- Dividend Yield
- SACH 19.05%
- TPST N/A
- EPS Growth
- SACH N/A
- TPST N/A
- EPS
- SACH N/A
- TPST N/A
- Revenue
- SACH N/A
- TPST N/A
- Revenue This Year
- SACH N/A
- TPST N/A
- Revenue Next Year
- SACH $6.63
- TPST N/A
- P/E Ratio
- SACH N/A
- TPST N/A
- Revenue Growth
- SACH N/A
- TPST N/A
- 52 Week Low
- SACH $0.80
- TPST $5.35
- 52 Week High
- SACH $2.51
- TPST $15.73
- Technical
- Relative Strength Index (RSI)
- SACH 40.98
- TPST 46.92
- Support Level
- SACH $1.06
- TPST $10.26
- Resistance Level
- SACH $1.15
- TPST $12.22
- Average True Range (ATR)
- SACH 0.05
- TPST 0.69
- MACD
- SACH -0.00
- TPST -0.01
- Stochastic Oscillator
- SACH 15.46
- TPST 1.88
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.